Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month

Company Overview - Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders with limited treatment options [3] - The company aims to transform the treatment approach for CNS conditions by developing therapeutic options with novel mechanisms of action [3] Industry Context - More than 37 million Americans suffer from migraine, making it the leading cause of disability among neurological disorders in the United States [2] - Migraine is associated with significant economic impacts, accounting for an estimated $78 billion in direct and indirect costs annually in the U.S. [2] - Surveys indicate that over 70% of migraine sufferers are not fully satisfied with their current treatment, and nearly 80% are open to trying new therapies [2]